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Abstract: Objective: The aim of this study was to clarify the role of IL-33 in tumor progression.  
Methods: Surgical specimens from 81 patients with squamous cell carcinoma of the tongue were 
studied using immunohistochemistry. Primary tumor sections were analyzed for IL-33 and ST2 
expression. To examine the influence of IL-33 on the microenvironment of the tumor, we determined 
the mast cell density (MCD) and microvessel density of the stroma.  
Results: Patients with high IL-33 expression had a significantly worse prognosis (p = 0.004). IL-33 
expression was significantly elevated in patients with local and nodal recurrence (p = 0.014 and p = 
0.019). ST2 expression was also associated with a worse prognosis (p = 0.024) and was significantly 
elevated in patients with nodal recurrence (p = 0.004). MCD was associated with worse prognosis (p = 
0.038) and correlated significantly with IL-33 expression (r = 0.626, p < 0.001). Micovessels in the 
stroma were significantly increased in the high IL-33 group (p < 0.001).  
Conclusion: These data suggest that the IL-33/ST2 axis contributes to tumor aggressiveness and affects 
the tumor microenvironment. Immunohistochemical evaluation of IL-33 and ST2 is useful for 





June 10, 2014 
Ken-ichi Nibu, 
Editor-in-Chief, Auris Nasus Larynx 
 
Dear Professor Nibu 
 
 
 We are grateful for the opportunity to revise our paper „ANL-D-14-00096‟ entitled 
“Expression of interleukin-33 is correlated with poor prognosis in patients with squamous cell 
carcinoma of the tongue” and the valuable comments of the two reviewers.  
            We have revised the manuscript according to the comments from reviewers. We added 
the information for ethical aspect in materials and methods part and altered an equivocal 
expression about specimens to clearer one. We also examined the relationship of the prognosis of 
the high IL-33 patients with postoperative adjuvant therapy. 
 We attach here our revised manuscript, as well as a point-by-point response to the 
reviewers‟ comments. 
 
 We now hope that our paper will be suitable for publication in Auris Nasus Larynx and 
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Response to the reviewers’ comments 
 
We would like to thank all reviewers for their encouraging and constructive comments that 
have helped us improve the manuscript. We have modified our manuscript ‘ANL-D-14-
00096’ along the lines suggested. Our point-by-point responses are listed below. 
 
 
Reviewer #1:  
 
This is an interesting, well written report investigating the role of IL-33/ST2 axis in oral 
cancer. The authors indicate that immunohistochemical evaluation of IL-33/ST2 is useful for 
identifying patients at a high risk for poor prognosis. The study is well designed and the basic 
(immunohistochemical) analyses appear to be well done. Although preliminary and does not 
indicate a direct effect in oral carcinogenesis, the conclusion seems to be sufficient to 
understand that IL33expression is an useful prognostic marker. 




We really appreciate that this reviewer finds our data interesting. We addressed her/his two 
issues as requested. 
 
1. This study includes immunohistochemical analysis of tissue samples of patients. Therefore, 
it is to be desired that authors should describe some comments with regard to the ethical 
aspect. 
*Detailed Response to Reviewers
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We agree with the reviewer’ opinion. We added the information for ethical aspect to line 105, 
106 in materials and methods part. 
 
2. A multivariant analysis is desired to confirm that IL33expression is an independent 
prognostic factor. 
 
A cox proportional hazards regression analysis of clinical factors, including sex, age, 
histologic type, T classification, N classification, expression of IL-33, expression of ST2 and 
MCD was performed. Univariate analyses were done initially, and then clinical factors that 
were identified as significantly associated with the disease-free survival rate were included in 
a multivariate analysis.  
The univariate analysis demonstrated that IL-33, ST2, and MCD were significant predictors 
for prognosis. However, there was no significant predictor in the multivariate analysis. We 
consider that this is because IL-33 expression correlated with ST2 expression and IL-33 
expression also correlated with MCD. 
 
A cox proportional hazards regression analysis of prognostic factors associated with the disease-free survival rate 
Prognostic factor                    p value  RR     95% CI  
Univariate analysis     
Sex (male versus female)             0.155 0.589   0.284-1.222  
Age (≦60 versus >60)             0.331 1.443   0.689-3.024  
Histologic type (WD versus MD/PD)     0.508 1.385   0.528-3.634  
T classification (T1+2 versus T3+4)     0.749 1.160   0.467-2.880  
N classification (pN0 versus pN1-3)     0.568 1.282   0.547-3.008  
Expression of IL-33 (high versus low)      0.007 ＊ 3.241   1.383-7.596  
Expression of ST2 (high versus low)      0.030 ＊ 2.473   1.094-5.593  
MCD (high versus low)             0.045 ＊ 2.242   1.020-4.931  
Multivariate analysis     
Expression of IL-33 (high versus low)     0.084 2.499   0.884-7.069  
Expression of ST2 (high versus low)      0.608 1.320   0.457-3.811  
MCD (high versus low)             0.691 1.219   0.458-3.246  






Several biomarkers which correlate with prognosis of SCC have been reported in the head 
and neck region. The authors reported expression of IL-33 in the tongue SCC and its 
potentials for predicting prognosis of the patients. This information may shed light to this 




We thank the reviewer for this excellent suggestion and finding our data convincing. We 
answered the questions that were found in reviewer’ text. 
 
1. "2.2. Immunohistochemical analysis 
The specimens, including the primary tumors, were fixed in 10% formalin solution and 
embedded in paraffin." 
This sentence means that all specimens were not primary lesions, that is tongue carcinoma. If 
so, were other specimens obtained from lymph node? Show us percentages of specimens from 
primary lesion. In addition, was there any difference between primary and metastatic lesion? 
 
Sorry for our sentence which caused misunderstanding. We meant that all specimens were the 
primary tumors. We didn’t evaluate the other specimens like lymph node. 
We have corrected the sentence at line 121 intelligibly. 
 
2. Concerning LN metastasis, did you estimate an extranodal extension? If so, was that 
related to high IL-33? 
 4 
 
This is a very good point. Although an extranodal extension also weighs on our mind, we did 
not estimate it in this study. However, most of IL-33 positive patients developed regional LN 
recurrences or residual diseases. So, we speculate IL-33 might have contributed to 
extracapsular invasion. 
 
3. Is there any different prognosis among the high IL-33patients with/ without postoperative 
adjuvant therapy? 
 
To examine the relationship of the prognosis of the high IL-33 patients with postoperative 
adjuvant therapy, Kaplan–Meier survival analysis was performed and differences between 
curves were analyzed using the log-rank test. Of the 41 patients assigned to the high IL-33 
group, 14 patients underwent postoperative treatment. Although the patients with 
postoperative treatment tended to have better prognosis than those without postoperative 
treatment, there was no significant difference between the two (p = 0.145). 
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Abstract 26 
Objective: The aim of this study was to clarify the role of IL-33 in tumor progression.  27 
Methods: Surgical specimens from 81 patients with squamous cell carcinoma of the tongue 28 
were studied using immunohistochemistry. Primary tumor sections were analyzed for IL-33 29 
and ST2 expression. To examine the influence of IL-33 on the microenvironment of the 30 
tumor, we determined the mast cell density (MCD) and microvessel density of the stroma.  31 
Results: Patients with high IL-33 expression had a significantly worse prognosis (p = 0.004). 32 
IL-33 expression was significantly elevated in patients with local and nodal recurrence (p = 33 
0.014 and p = 0.019). ST2 expression was also associated with a worse prognosis (p = 0.024) 34 
and was significantly elevated in patients with nodal recurrence (p = 0.004). MCD was 35 
associated with worse prognosis (p = 0.038) and correlated significantly with IL-33 36 
expression (r = 0.626, p < 0.001). Micovessels in the stroma were significantly increased in 37 
the high IL-33 group (p < 0.001).  38 
Conclusion: These data suggest that the IL-33/ST2 axis contributes to tumor aggressiveness 39 
and affects the tumor microenvironment. Immunohistochemical evaluation of IL-33 and ST2 40 
is useful for identifying patients at a high risk for poor prognosis. 41 
 42 
 43 
Key words: interleukin-33, ST2, tongue squamous cell carcinoma, inflammation, mast cell, 44 







1. Introduction 51 
 52 
Tongue squamous cell carcinoma (SCC) is one of the most common head and neck 53 
cancers. Prognosis is associated with clinical stage, particularly nodal status. Therefore, the 54 
expression of metastasis-related factors such as matrix metalloproteinases, syndecans, and 55 
vascular endothelial growth factor predicts the treatment outcome of patients with tongue 56 
SCC [1-4]. Tongue SCC is associated with inflammation in the oral cavity, which is mediated 57 
by chronic trauma such as smoking, alcohol consumption, and periodontal disease and is 58 
associated with oral carcinogenesis [5]. Moreover, inflammation promotes cancer 59 
development and progression through its effects on the tumor microenvironment [6]. 60 
Inflammatory mediators and specific cell types influence the migration, invasion, and 61 
metastasis of tumor cells [6]. Therefore, efficacious therapies must be developed for targeting 62 
inflammation in patients with cancer. 63 
Interleukin (IL)-33 is a member of the IL-1 family and functions as a ligand for ST2, 64 
which is a member of the IL-1 receptor family. IL-33 is expressed by many cell types, 65 
including epithelial cells, endothelial cells, smooth muscle cells, fibroblasts, and activated 66 
macrophages [7]. In contrast, mast cells (MCs), Th2 cells, eosinophils, basophils, epithelial 67 
cells, and endothelial cells express ST2 [8-12]. Unlike other members of the IL-1 family, the 68 
cleavage site for caspases is located within the IL-1-like domain of IL-33, and the cleavage 69 
products are biologically inactive. 70 
Biologically active, full-length IL-33 is released when cells sense inflammatory signals or 71 
undergo necrosis. Therefore, IL-33 acts as an endogenous danger signal or “alarmin” 72 
[8,13,14]. Binding of extracellular IL-33 to ST2 preferentially induces Th2-type immune 73 
responses with concomitant expression of Th2-associated cytokines [7]. It is clear that the 74 
potency of IL-33 for activating several immunocytes probably impacts inflammation. For 75 
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example, IL-33 is expressed by patients with chronic gastritis, chronic hepatitis, and 76 
inflammatory bowel disease [15-17]. Inflammatory diseases increase the risk of developing 77 
cancer, suggesting that IL-33 may play an important role in cancer pathogenesis [18,19]. 78 
IL-33 affects the phenotype of cell types that express the transmembrane isoform of ST2. 79 
The inflammatory component of a neoplasm may include a diverse leukocyte population, and 80 
ST2 is expressed on many of these inflammatory cells, including MCs, macrophages, 81 
dendritic cells, eosinophils, and neutrophils [8,20]. Among the inflammatory cells in the 82 
stroma of the tumor, MCs are important because they secrete cytokines and chemokines, and 83 
influence the phenotypes of other cells through these soluble mediators as well as through 84 
cell–cell interaction. Moreover, MCs reside in the connective tissue surrounding tumors, and 85 
the accumulation of MCs is often associated with poor prognosis [21,22]. IL-33 is a potent 86 
activator of MCs and induces their degranulation and maturation, promotes survival, and 87 
induces the production of several proinflammatory cytokines [9,23]. Therefore, it is 88 
reasonable to assume that IL-33 contributes significantly to the malignant potential of tumor 89 
cells through the formation of an inflammatory tumor microenvironment. 90 
We reported the carcinogenic role of activation-induced cytidine deaminase (AID), which 91 
is induced by an inflammatory environment [24]. However, the expression of AID does not 92 
correlate with the progression of tongue SCC, which diverted our attention to IL-33. 93 
Inflammation mediated by tobacco smoking, which is associated with tongue SCC, induces 94 
the expression of IL-33/ST2 in mice [25]. In the present study, we determined the expression 95 
of IL-33 in patients with tongue SCC using immunohistochemistry and assessed the 96 
relationship between the expression of IL-33 and prognosis of tongue SCC. Furthermore, to 97 
evaluate the influence of IL-33 on the tumor microenvironment, we determined the density of 98 
MCs in the stroma surrounding the tumor. 99 
 100 
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2. Materials and methods 101 
 102 
2.1. Patients and specimens 103 
 104 
  This study included 81 patients who were diagnosed with tongue SCC. Informed consent 105 
was obtained from all patients in accordance with our institutional guidelines. The patient 106 
characteristics are presented in Table 1. Their clinical status was determined according to the 107 
TNM classification system of the Union Internationale Contre le Cancer [26]. All patients 108 
underwent surgery at the Division of Otolaryngology-Head and Neck Surgery, Kanazawa 109 
University Hospital between 1982 and 2007. Resection of the primary tongue tumor was 110 
performed in all patients, and neck dissection was performed in 53 patients with clinically 111 
positive nodes or tumors that were more advanced than stage T2. The 22 patients with 112 
positive margins or pathologically positive lymph node metastasis underwent postoperative 113 
treatment, including radiotherapy. The mean follow-up period was 50.7 months (median, 41 114 
months; range, 1–131 months). Disease-free survival was calculated from the date of 115 
treatment until the time of local recurrence or the detection of metastases, including 116 
recurrence in the neck lymph nodes. 117 
 118 
2.2. Immunohistochemical analysis 119 
 120 
  All specimens were the primary tumors. They were fixed in 10% formalin solution and 121 
embedded in paraffin. Serial 3-μm-thick sections were cut from each block, dewaxed, and 122 
rehydrated. Antigen retrieval was performed by heating slides for 30 min in citrate buffer (pH 123 
6.0) at 90ºC, cooling for 20 min, and washing. Endogenous peroxidase was quenched with 124 
methanol and 3% H2O2 for 10 min, followed by incubation with Protein Block Serum 125 
 6 
(DakoCytomation, Glostrup, Denmark) to decrease nonspecific binding. Then, the sections 126 
were incubated overnight at 4ºC with primary antibodies against IL-33 (diluted 1:100, rabbit 127 
polyclonal, Medical & Biological Laboratories, Nagoya, Japan), ST2 (diluted 1:100, mouse 128 
monoclonal, Medical & Biological Laboratories), mast cell tryptase (diluted 1:1000, mouse 129 
monoclonal, Dako), and CD34 (diluted 1:50, mouse monoclonal, Dako). The sections were 130 
incubated with secondary antibodies conjugated to a peroxidase-labeled polymer 131 
(EnVision™+ system, Dako) at room temperature for 30 min. Immune complexes were 132 
detected using 3,3’-diaminobenzidine tetrahydrochloride, and the sections were 133 
counterstained with hematoxylin. The specificities of the staining reactions were confirmed 134 
using nonimmune serum instead of the primary antibody. 135 
 136 
2.3. IL-33 and ST2 expression and mast cell density (MCD) 137 
 138 
  Two investigators with no prior knowledge of the clinical data assessed the microvessel 139 
counts and expression of IL-33, ST2, and tryptase. 140 
  Staining results for IL-33 and ST2 were classified by estimating the percentage of tumor 141 
cells showing specific immunoreactivity. Two areas with a high density of stained cells were 142 
selected in a 40× field, following which the number of immunoreactive cells and the total 143 
number of tumor cells were counted in two areas in a 200× field. The percentage of positive 144 
cells calculated as an average of two counts was used as the expression score. The antibody 145 
against tryptase was used to determine MCD in the stroma surrounding the tumor and was 146 
classified by estimating the percentage of tryptase-positive cells in the stroma. The two areas 147 
with the highest MCD were identified in a 200× field. Then, the number of tryptase-positive 148 
cells and the total number of stromal cells were counted in these areas in a 400× field. To 149 
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correlate these results with prognosis, the expression scores and MCD values were divided 150 
into high and low groups using median scores as cutoff values. 151 
 152 
2.4. Microvessel density (MVD) 153 
 154 
  MVD was calculated by counting the number of vessels stained with CD-34 according to 155 
Weidner et al [27]. Three areas with the highest MVD were selected in a 40× to 100× field. 156 
Then, microvessels were counted in the three areas in a 200× field. MVD was calculated as 157 
the average of three counts. Any brownish-staining endothelial cell or endothelial cell cluster 158 
was considered as a single microvessel. 159 
 160 
2.5. Statistical analysis 161 
 162 
  IBM SPSS Statistics version 19 (IBM, Armonk, New York, USA) was used for data 163 
analysis. The clinical characteristics of patients in terms of IL-33 and ST2 expression and 164 
MCD were analyzed using Fisher’s exact test and the chi-square test. The relationship 165 
between IL-33 and ST2 expression and MCD was evaluated using Spearman’s rank 166 
correlation coefficient. Survival curves were evaluated using the Kaplan–Meier method, and 167 
differences between curves were analyzed using the log-rank test. IL-33 expression in 168 
relation to MVD was analyzed using the Mann–Whitney U test. A p value of <0.05 was 169 
considered statistically significant. 170 
 171 
3. Results 172 
 173 
3.1. IL-33 and ST2 expression 174 
 8 
 175 
  IL-33 was detected only in the nuclei of normal epithelial cells, and ST2 was observed 176 
most frequently, but faintly, in the membrane and cytoplasm of cells in the prickle cell to 177 
horny layers (Fig. 1A and 1B). In contrast, IL-33 was detected in the nuclei and cytoplasm of 178 
SCC cells (Fig. 1C). ST2 expression was most prominent in the membrane and cytoplasm of 179 
the tumor cells (Fig. 1D). IL-33 and ST2 expression were observed in 100% and 95.1% of the 180 
samples, respectively. The mean expression scores for IL-33 and ST2 in the tumor cells were 181 
41.59% ± 23.89% and 22.14% ± 19.29%, respectively. 182 
 183 
3.2. MCD 184 
 185 
  MCs were detected by staining with the anti-tryptase antibody in all samples, and they 186 
were located in the stroma at the margins of the tumors (Fig. 1E). The mean MCD was 187 
12.54% ± 11.60%. 188 
 189 
3.3. Correlation of IL-33 and ST2 expression with MCD 190 
 191 
  IL-33 expression correlated significantly with ST2 expression (r = 0.558, p < 0.001, Fig. 192 
2A). IL-33 expression also correlated with MCD (r = 0.626, p < 0.001, Fig. 2B). 193 
 194 
3.4. Association of IL-33 and ST2 expression and MCD with disease-free survival 195 
 196 
  To evaluate the prognostic value of IL-33 and ST2 expression and MCD in patients with 197 
tongue SCC, patients were stratified into high and low groups as described in Methods. The 198 
median expression scores for IL-33 and ST2 were 46% and 14%, respectively, and 9% for 199 
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MCD. These scores were used as cutoff values. Of the 81 specimens, 41 were assigned to the 200 
high group. Kaplan–Meier survival analysis revealed that the prognosis was poorer for the 201 
high IL-33 and ST2 groups than for the low IL-33 and ST2 groups (p = 0.004 and 0.024, 202 
respectively, Fig. 3A and 3B). Similarly, the disease-free survival rate was significantly 203 
lower in the high MCD group than in the low MCD group (p = 0.038, Fig. 3C). 204 
  Furthermore, to examine the relationship of the prognosis of the high IL-33 patients with 205 
postoperative adjuvant therapy, Kaplan–Meier survival analysis was performed. Of the 41 206 
patients assigned to the high IL-33 group, 14 patients underwent postoperative radiotherapy. 207 
Although the patients with postoperative treatment tended to have better prognosis than those 208 
without postoperative treatment, there was no significant difference between the two (p = 209 
0.145 data not shown). 210 
 211 
3.5. Relationship between clinicopathological features and expression of IL-33, ST2, and 212 
MCD 213 
 214 
  The relationship between immunohistochemical data and clinicopathological factors of the 215 
81 patients, including age, sex, T classification, N classification, clinical stage, local 216 
recurrence, nodal recurrence, and distant metastatic recurrence, was evaluated using Fisher’s 217 
exact test and the chi-square test (Table 1). Local recurrence was significantly more frequent 218 
among patients in the high IL-33 group than among those in the low IL-33 group. IL-33 and 219 
ST2 expression and MCD were significantly associated with nodal recurrence. A higher 220 
frequency of nodal recurrence associated significantly with the high IL-33, ST2, and MCD 221 
groups, but not with the low groups. There were no other significant differences in 222 
clinicopathological features between the low and high IL-33, ST2, and MCD groups. 223 
 224 
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3.6. Relationship between IL-33 expression and MVD 225
 226
  Vascular endothelial cells reacted specifically with the antibody against CD34. The 227
microvessels were detected as scattered structures in the stroma of the tumor (Fig. 1F). 228
MVDs in all patients ranged from 7 to 75 (mean, 34.41 ± 16.46). The correlation between IL-229
33 expression and MVD is shown in Table 2. MVD was significantly higher in the high IL-230




Little is known about the role of IL-33 in the pathogenesis and progression of carcinomas 235
[18,19]. This is the first study, to our knowledge, that demonstrates IL-33 expression in 236
tongue SCC and suggests its role in the progression of this tumor. We detected the expression 237
of IL-33 and ST2 in patients with tongue SCC by immunohistochemistry and found that the 238
expression of IL-33 was significantly correlated with poor prognosis. 239
We do not go further for the molecular mechanism which is attributable to the prognostic 240
value of IL-33 in this study, however, one of possible mechanism for IL-33-mediated 241
malignant progression could be an activation of ST2 downstream signal transduction such as 242
nuclear factor-κB (NF-κB). The IL-33/ST2 axis leads to activation of NF-κB [8,20,28], 243
which is a key inducer of innate immunity and inflammation and has emerged as an 244
important endogenous tumor promoter [6,29]. NF-κBactivates the expression of genes 245
encoding inflammatory cytokines, adhesion molecules, enzymes of the prostaglandin-246
synthesis pathway, inducible nitric oxide synthase, and angiogenic factors. Thus, activation 247
of NF-κB through the IL-33 signaling pathway may cause cancer progression.    248
 11 
Th2-type responses induced by IL-33 may contribute to tumor progression. An induction 249 
of IL-33 enhances Th2 immune response and polarizes naïve T cells to produce IL-5 and IL-250 
13 independently of IL-4 [8,20]. High levels of Th2 cytokines are observed in the tumor 251 
microenvironment and peripheral blood of patients with certain cancers [30]. Moreover, 252 
analysis of ST2-deficient mice demonstrates that the Th2-associated immune response is 253 
inhibited in the absence of IL-33/ST2 signaling, leading to delayed induction of mammary 254 
tumors and slower tumor growth and progression [31,32].  255 
In addition, IL-33 induces angiogenesis and vasopermeability [33]. Our present study 256 
reveals that IL-33 expression strongly correlated with MVD and was significantly associated 257 
with local and nodal recurrence, but not clinical stage. These results suggest that IL-33 258 
influences the malignant potential of the tumor through the promotion of angiogenesis and 259 
activation of ST2 signaling.
 260 
We also demonstrate that IL-33 expression significantly correlated with MCD, suggesting 261 
that IL-33 contributes to tumor progression by activating MCs. An induction of IL-33 262 
potently activates the innate immune system by inducing pro-inflammatory cytokines and 263 
chemokine production through the activation of MCs. It also induces the degranulation of 264 
IgE-primed MCs and enhances their maturation and survival [8,20]. The MCD generally 265 
correlates with poor outcome in patients with tongue SCC [34,35]. Furthermore, other studies 266 
reveal that IL-33 activates macrophages, dendritic cells, eosinophils, and neutrophils [8,20]. 267 
These cells play important roles in enhancing an inflammatory environment that promotes 268 
tumor growth in the surrounding tissue [6]. IL-33 may recruit these inflammatory cells to the 269 
stroma of the tumor, subsequently enhancing tumor aggressiveness. 270 
In conclusion, the high expression level of IL-33 is a risk factor for poor prognosis in 271 
patients with tongue SCC. In the high IL-33 patients, postoperative radiotherapy tended to 272 
improve the prognosis. Those patients received postoperative radiotherapy were likely to 273 
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have poor prognosis. Therefore, this result suggests that postoperative radiotherapy may be 274 
effective in the treatment of the high IL-33 patients with positive margins or pathologically 275 
positive lymph node metastasis. 276 
IL-33 and ST2 may represent therapeutic targets for tongue SCC. Although it remains 277 
unclear how IL-33/ST2 axis contributes to tumor progression, our findings indicate that the 278 
IL-33/ST2 axis promotes the malignant potential of tumor by affecting the tumor as well as 279 
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Figure legends 398 
 399 
Figure 1. Immunohistochemical analysis of IL-33 and ST2 expression in normal epithelial 400 
and tumor cells (A–D) and tryptase (E) and CD34 (F) expression. (original magnification 401 
×200) 402 
A: IL-33 is detected in the nuclei of normal epithelial cells. 403 
B: ST2 is faintly detected in the membrane and cytoplasm of normal epithelial cells. 404 
C: IL-33 is detected in the nuclei and cytoplasm of tumor cells. 405 
D: Intense staining of ST2 in the membrane and cytoplasm of tumor cells. 406 
E: MCs were detected as dark-brown stained cells using an anti-tryptase antibody. They were 407 
also located in the stroma at the tumor margins. 408 
F: CD34 expression in vascular endothelial cells (stained dark brown) in the stroma of the 409 
tumor. 410 
 411 
Figure 2. Correlation between IL-33 and ST2 expression and MCD in tongue SCC. 412 
A: Correlation between IL-33 and ST2 expression. IL-33 expression correlated significantly 413 
with ST2 expression (Spearman’s rank correlation coefficient). 414 
B: Correlation between IL-33 expression and MCD. IL-33 expression correlated significantly 415 
with MCD. 416 
 417 
Figure 3. Kaplan–Meier analysis of disease-free survival rates.  418 
Differences between the curves were analyzed using the log-rank test. Disease-free survival 419 
rates in relation to IL-33 expression (A), ST2 expression (B), and MCD (C). 420 
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Abstract 
Objective: The aim of this study was to clarify the role of IL-33 in tumor progression.  
Methods: Surgical specimens from 81 patients with squamous cell carcinoma of the tongue 
were studied using immunohistochemistry. Primary tumor sections were analyzed for IL-33 
and ST2 expression. To examine the influence of IL-33 on the microenvironment of the 
tumor, we determined the mast cell density (MCD) and microvessel density of the stroma.  
Results: Patients with high IL-33 expression had a significantly worse prognosis (p = 0.004). 
IL-33 expression was significantly elevated in patients with local and nodal recurrence (p = 
0.014 and p = 0.019). ST2 expression was also associated with a worse prognosis (p = 0.024) 
and was significantly elevated in patients with nodal recurrence (p = 0.004). MCD was 
associated with worse prognosis (p = 0.038) and correlated significantly with IL-33 
expression (r = 0.626, p < 0.001). Micovessels in the stroma were significantly increased in 
the high IL-33 group (p < 0.001).  
Conclusion: These data suggest that the IL-33/ST2 axis contributes to tumor aggressiveness 
and affects the tumor microenvironment. Immunohistochemical evaluation of IL-33 and ST2 
is useful for identifying patients at a high risk for poor prognosis. 
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Tongue squamous cell carcinoma (SCC) is one of the most common head and neck 
cancers. Prognosis is associated with clinical stage, particularly nodal status. Therefore, the 
expression of metastasis-related factors such as matrix metalloproteinases, syndecans, and 
vascular endothelial growth factor predicts the treatment outcome of patients with tongue 
SCC [1-4]. Tongue SCC is associated with inflammation in the oral cavity, which is mediated 
by chronic trauma such as smoking, alcohol consumption, and periodontal disease and is 
associated with oral carcinogenesis [5]. Moreover, inflammation promotes cancer 
development and progression through its effects on the tumor microenvironment [6]. 
Inflammatory mediators and specific cell types influence the migration, invasion, and 
metastasis of tumor cells [6]. Therefore, efficacious therapies must be developed for targeting 
inflammation in patients with cancer. 
Interleukin (IL)-33 is a member of the IL-1 family and functions as a ligand for ST2, 
which is a member of the IL-1 receptor family. IL-33 is expressed by many cell types, 
including epithelial cells, endothelial cells, smooth muscle cells, fibroblasts, and activated 
macrophages [7]. In contrast, mast cells (MCs), Th2 cells, eosinophils, basophils, epithelial 
cells, and endothelial cells express ST2 [8-12]. Unlike other members of the IL-1 family, the 
cleavage site for caspases is located within the IL-1-like domain of IL-33, and the cleavage 
products are biologically inactive. 
Biologically active, full-length IL-33 is released when cells sense inflammatory signals or 
undergo necrosis. Therefore, IL-33 acts as an endogenous danger signal or “alarmin” 
[8,13,14]. Binding of extracellular IL-33 to ST2 preferentially induces Th2-type immune 
responses with concomitant expression of Th2-associated cytokines [7]. It is clear that the 
potency of IL-33 for activating several immunocytes probably impacts inflammation. For 
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example, IL-33 is expressed by patients with chronic gastritis, chronic hepatitis, and 
inflammatory bowel disease [15-17]. Inflammatory diseases increase the risk of developing 
cancer, suggesting that IL-33 may play an important role in cancer pathogenesis [18,19]. 
IL-33 affects the phenotype of cell types that express the transmembrane isoform of ST2. 
The inflammatory component of a neoplasm may include a diverse leukocyte population, and 
ST2 is expressed on many of these inflammatory cells, including MCs, macrophages, 
dendritic cells, eosinophils, and neutrophils [8,20]. Among the inflammatory cells in the 
stroma of the tumor, MCs are important because they secrete cytokines and chemokines, and 
influence the phenotypes of other cells through these soluble mediators as well as through 
cell–cell interaction. Moreover, MCs reside in the connective tissue surrounding tumors, and 
the accumulation of MCs is often associated with poor prognosis [21,22]. IL-33 is a potent 
activator of MCs and induces their degranulation and maturation, promotes survival, and 
induces the production of several proinflammatory cytokines [9,23]. Therefore, it is 
reasonable to assume that IL-33 contributes significantly to the malignant potential of tumor 
cells through the formation of an inflammatory tumor microenvironment. 
We reported the carcinogenic role of activation-induced cytidine deaminase (AID), which 
is induced by an inflammatory environment [24]. However, the expression of AID does not 
correlate with the progression of tongue SCC, which diverted our attention to IL-33. 
Inflammation mediated by tobacco smoking, which is associated with tongue SCC, induces 
the expression of IL-33/ST2 in mice [25]. In the present study, we determined the expression 
of IL-33 in patients with tongue SCC using immunohistochemistry and assessed the 
relationship between the expression of IL-33 and prognosis of tongue SCC. Furthermore, to 
evaluate the influence of IL-33 on the tumor microenvironment, we determined the density of 
MCs in the stroma surrounding the tumor. 
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2. Materials and methods 
 
2.1. Patients and specimens 
 
  This study included 81 patients who were diagnosed with tongue SCC. Informed consent 
was obtained from all patients in accordance with our institutional guidelines. The patient 
characteristics are presented in Table 1. Their clinical status was determined according to the 
TNM classification system of the Union Internationale Contre le Cancer [26]. All patients 
underwent surgery at the Division of Otolaryngology-Head and Neck Surgery, Kanazawa 
University Hospital between 1982 and 2007. Resection of the primary tongue tumor was 
performed in all patients, and neck dissection was performed in 53 patients with clinically 
positive nodes or tumors that were more advanced than stage T2. The 22 patients with 
positive margins or pathologically positive lymph node metastasis underwent postoperative 
treatment, including radiotherapy. The mean follow-up period was 50.7 months (median, 41 
months; range, 1–131 months). Disease-free survival was calculated from the date of 
treatment until the time of local recurrence or the detection of metastases, including 
recurrence in the neck lymph nodes. 
 
2.2. Immunohistochemical analysis 
 
  All specimens were the primary tumors. They were fixed in 10% formalin solution and 
embedded in paraffin. Serial 3-μm-thick sections were cut from each block, dewaxed, and 
rehydrated. Antigen retrieval was performed by heating slides for 30 min in citrate buffer (pH 
6.0) at 90ºC, cooling for 20 min, and washing. Endogenous peroxidase was quenched with 
methanol and 3% H2O2 for 10 min, followed by incubation with Protein Block Serum 
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(DakoCytomation, Glostrup, Denmark) to decrease nonspecific binding. Then, the sections 
were incubated overnight at 4ºC with primary antibodies against IL-33 (diluted 1:100, rabbit 
polyclonal, Medical & Biological Laboratories, Nagoya, Japan), ST2 (diluted 1:100, mouse 
monoclonal, Medical & Biological Laboratories), mast cell tryptase (diluted 1:1000, mouse 
monoclonal, Dako), and CD34 (diluted 1:50, mouse monoclonal, Dako). The sections were 
incubated with secondary antibodies conjugated to a peroxidase-labeled polymer 
(EnVision™+ system, Dako) at room temperature for 30 min. Immune complexes were 
detected using 3,3’-diaminobenzidine tetrahydrochloride, and the sections were 
counterstained with hematoxylin. The specificities of the staining reactions were confirmed 
using nonimmune serum instead of the primary antibody. 
 
2.3. IL-33 and ST2 expression and mast cell density (MCD) 
 
  Two investigators with no prior knowledge of the clinical data assessed the microvessel 
counts and expression of IL-33, ST2, and tryptase. 
  Staining results for IL-33 and ST2 were classified by estimating the percentage of tumor 
cells showing specific immunoreactivity. Two areas with a high density of stained cells were 
selected in a 40× field, following which the number of immunoreactive cells and the total 
number of tumor cells were counted in two areas in a 200× field. The percentage of positive 
cells calculated as an average of two counts was used as the expression score. The antibody 
against tryptase was used to determine MCD in the stroma surrounding the tumor and was 
classified by estimating the percentage of tryptase-positive cells in the stroma. The two areas 
with the highest MCD were identified in a 200× field. Then, the number of tryptase-positive 
cells and the total number of stromal cells were counted in these areas in a 400× field. To 
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correlate these results with prognosis, the expression scores and MCD values were divided 
into high and low groups using median scores as cutoff values. 
 
2.4. Microvessel density (MVD) 
 
  MVD was calculated by counting the number of vessels stained with CD-34 according to 
Weidner et al [27]. Three areas with the highest MVD were selected in a 40× to 100× field. 
Then, microvessels were counted in the three areas in a 200× field. MVD was calculated as 
the average of three counts. Any brownish-staining endothelial cell or endothelial cell cluster 
was considered as a single microvessel. 
 
2.5. Statistical analysis 
 
  IBM SPSS Statistics version 19 (IBM, Armonk, New York, USA) was used for data 
analysis. The clinical characteristics of patients in terms of IL-33 and ST2 expression and 
MCD were analyzed using Fisher’s exact test and the chi-square test. The relationship 
between IL-33 and ST2 expression and MCD was evaluated using Spearman’s rank 
correlation coefficient. Survival curves were evaluated using the Kaplan–Meier method, and 
differences between curves were analyzed using the log-rank test. IL-33 expression in 
relation to MVD was analyzed using the Mann–Whitney U test. A p value of <0.05 was 




3.1. IL-33 and ST2 expression 
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  IL-33 was detected only in the nuclei of normal epithelial cells, and ST2 was observed 
most frequently, but faintly, in the membrane and cytoplasm of cells in the prickle cell to 
horny layers (Fig. 1A and 1B). In contrast, IL-33 was detected in the nuclei and cytoplasm of 
SCC cells (Fig. 1C). ST2 expression was most prominent in the membrane and cytoplasm of 
the tumor cells (Fig. 1D). IL-33 and ST2 expression were observed in 100% and 95.1% of the 
samples, respectively. The mean expression scores for IL-33 and ST2 in the tumor cells were 




  MCs were detected by staining with the anti-tryptase antibody in all samples, and they 
were located in the stroma at the margins of the tumors (Fig. 1E). The mean MCD was 
12.54% ± 11.60%. 
 
3.3. Correlation of IL-33 and ST2 expression with MCD 
 
  IL-33 expression correlated significantly with ST2 expression (r = 0.558, p < 0.001, Fig. 
2A). IL-33 expression also correlated with MCD (r = 0.626, p < 0.001, Fig. 2B). 
 
3.4. Association of IL-33 and ST2 expression and MCD with disease-free survival 
 
  To evaluate the prognostic value of IL-33 and ST2 expression and MCD in patients with 
tongue SCC, patients were stratified into high and low groups as described in Methods. The 
median expression scores for IL-33 and ST2 were 46% and 14%, respectively, and 9% for 
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MCD. These scores were used as cutoff values. Of the 81 specimens, 41 were assigned to the 
high group. Kaplan–Meier survival analysis revealed that the prognosis was poorer for the 
high IL-33 and ST2 groups than for the low IL-33 and ST2 groups (p = 0.004 and 0.024, 
respectively, Fig. 3A and 3B). Similarly, the disease-free survival rate was significantly 
lower in the high MCD group than in the low MCD group (p = 0.038, Fig. 3C). 
  Furthermore, to examine the relationship of the prognosis of the high IL-33 patients with 
postoperative adjuvant therapy, Kaplan–Meier survival analysis was performed. Of the 41 
patients assigned to the high IL-33 group, 14 patients underwent postoperative radiotherapy. 
Although the patients with postoperative treatment tended to have better prognosis than those 
without postoperative treatment, there was no significant difference between the two (p = 
0.145 data not shown). 
 
3.5. Relationship between clinicopathological features and expression of IL-33, ST2, and 
MCD 
 
  The relationship between immunohistochemical data and clinicopathological factors of the 
81 patients, including age, sex, T classification, N classification, clinical stage, local 
recurrence, nodal recurrence, and distant metastatic recurrence, was evaluated using Fisher’s 
exact test and the chi-square test (Table 1). Local recurrence was significantly more frequent 
among patients in the high IL-33 group than among those in the low IL-33 group. IL-33 and 
ST2 expression and MCD were significantly associated with nodal recurrence. A higher 
frequency of nodal recurrence associated significantly with the high IL-33, ST2, and MCD 
groups, but not with the low groups. There were no other significant differences in 
clinicopathological features between the low and high IL-33, ST2, and MCD groups. 
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3.6. Relationship between IL-33 expression and MVD 
 
  Vascular endothelial cells reacted specifically with the antibody against CD34. The 
microvessels were detected as scattered structures in the stroma of the tumor (Fig. 1F). 
MVDs in all patients ranged from 7 to 75 (mean, 34.41 ± 16.46). The correlation between IL-
33 expression and MVD is shown in Table 2. MVD was significantly higher in the high IL-




Little is known about the role of IL-33 in the pathogenesis and progression of carcinomas 
[18,19]. This is the first study, to our knowledge, that demonstrates IL-33 expression in 
tongue SCC and suggests its role in the progression of this tumor. We detected the expression 
of IL-33 and ST2 in patients with tongue SCC by immunohistochemistry and found that the 
expression of IL-33 was significantly correlated with poor prognosis. 
We do not go further for the molecular mechanism which is attributable to the prognostic 
value of IL-33 in this study, however, one of possible mechanism for IL-33-mediated 
malignant progression could be an activation of ST2 downstream signal transduction such as 
nuclear factor-κB (NF-κB). The IL-33/ST2 axis leads to activation of NF-κB [8,20,28], 
which is a key inducer of innate immunity and inflammation and has emerged as an 
important endogenous tumor promoter [6,29]. NF-κBactivates the expression of genes 
encoding inflammatory cytokines, adhesion molecules, enzymes of the prostaglandin-
synthesis pathway, inducible nitric oxide synthase, and angiogenic factors. Thus, activation 
of NF-κB through the IL-33 signaling pathway may cause cancer progression.    
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Th2-type responses induced by IL-33 may contribute to tumor progression. An induction 
of IL-33 enhances Th2 immune response and polarizes naïve T cells to produce IL-5 and IL-
13 independently of IL-4 [8,20]. High levels of Th2 cytokines are observed in the tumor 
microenvironment and peripheral blood of patients with certain cancers [30]. Moreover, 
analysis of ST2-deficient mice demonstrates that the Th2-associated immune response is 
inhibited in the absence of IL-33/ST2 signaling, leading to delayed induction of mammary 
tumors and slower tumor growth and progression [31,32].  
In addition, IL-33 induces angiogenesis and vasopermeability [33]. Our present study 
reveals that IL-33 expression strongly correlated with MVD and was significantly associated 
with local and nodal recurrence, but not clinical stage. These results suggest that IL-33 
influences the malignant potential of the tumor through the promotion of angiogenesis and 
activation of ST2 signaling.
 
We also demonstrate that IL-33 expression significantly correlated with MCD, suggesting 
that IL-33 contributes to tumor progression by activating MCs. An induction of IL-33 
potently activates the innate immune system by inducing pro-inflammatory cytokines and 
chemokine production through the activation of MCs. It also induces the degranulation of 
IgE-primed MCs and enhances their maturation and survival [8,20]. The MCD generally 
correlates with poor outcome in patients with tongue SCC [34,35]. Furthermore, other studies 
reveal that IL-33 activates macrophages, dendritic cells, eosinophils, and neutrophils [8,20]. 
These cells play important roles in enhancing an inflammatory environment that promotes 
tumor growth in the surrounding tissue [6]. IL-33 may recruit these inflammatory cells to the 
stroma of the tumor, subsequently enhancing tumor aggressiveness. 
In conclusion, the high expression level of IL-33 is a risk factor for poor prognosis in 
patients with tongue SCC. In the high IL-33 patients, postoperative radiotherapy tended to 
improve the prognosis. Those patients received postoperative radiotherapy were likely to 
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have poor prognosis. Therefore, this result suggests that postoperative radiotherapy may be 
effective in the treatment of the high IL-33 patients with positive margins or pathologically 
positive lymph node metastasis. 
IL-33 and ST2 may represent therapeutic targets for tongue SCC. Although it remains 
unclear how IL-33/ST2 axis contributes to tumor progression, our findings indicate that the 
IL-33/ST2 axis promotes the malignant potential of tumor by affecting the tumor as well as 
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Figure 1. Immunohistochemical analysis of IL-33 and ST2 expression in normal epithelial 
and tumor cells (A–D) and tryptase (E) and CD34 (F) expression. (original magnification 
×200) 
A: IL-33 is detected in the nuclei of normal epithelial cells. 
B: ST2 is faintly detected in the membrane and cytoplasm of normal epithelial cells. 
C: IL-33 is detected in the nuclei and cytoplasm of tumor cells. 
D: Intense staining of ST2 in the membrane and cytoplasm of tumor cells. 
E: MCs were detected as dark-brown stained cells using an anti-tryptase antibody. They were 
also located in the stroma at the tumor margins. 
F: CD34 expression in vascular endothelial cells (stained dark brown) in the stroma of the 
tumor. 
 
Figure 2. Correlation between IL-33 and ST2 expression and MCD in tongue SCC. 
A: Correlation between IL-33 and ST2 expression. IL-33 expression correlated significantly 
with ST2 expression (Spearman’s rank correlation coefficient). 
B: Correlation between IL-33 expression and MCD. IL-33 expression correlated significantly 
with MCD. 
 
Figure 3. Kaplan–Meier analysis of disease-free survival rates.  
Differences between the curves were analyzed using the log-rank test. Disease-free survival 
rates in relation to IL-33 expression (A), ST2 expression (B), and MCD (C). 
Table 1
Characteristic Samples Number of p Number of p Number of p
high IL-33 expresssion (%) high ST2 expression (%) high MCD (%)
Sex Male 50 24 (48.0) 0.550 25 (50.0) 0.888 25 (50.0) 0.888
Femal 31 17 (54.8) 16 (51.6) 16 (51.6)
Age ≦60 40 17 (42.5) 0.149 20 (50.0) 0.913 21 (52.5) 0.738
>60 41 24 (58.5) 21 (51.2) 20 (48.8)
Histologic type WD 70 37 (52.9) 0.349 37 (52.9) 0.349 36 (51.4) 0.756
MD/PD 11 4 (36.4) 4 (36.4) 5 (45.5)
T classification T1+T2 67 32 (47.8) 0.379 32 (47.8) 0.379 32 (47.8) 0.379
T3+T4 14 9 (64.3) 9 (64.3) 9 (64.3)
N classification pN0 62 32 (51.6) 0.798 34 (54.8) 0.198 35 (56.5) 0.070
pN1-3 19 9 (47.4) 7 (36.8) 6 (31.6)
Stage Ⅰ+Ⅱ 55 25 (45.5) 0.176 26 (47.3) 0.381 27 (49.1) 0.689
Ⅲ+Ⅳ 26 16 (61.5) 15 (57.7) 14 (53.8)
Local recurrence negative 71 32 (45.1) 0.014
＊
34 (47.9) 0.312 35 (49.3) 0.737
positive 10 9 (90.0) 7 (70.0) 6 (60.0)






positive 20 15 (75.0) 16 (80.0) 16 (80.0)
Distant metastatic recurrence negative 78 38 (48.7) 0.241 40 (51.3) 0.616 39 (50.0) 1.000
positive 3 3 (100.0) 1 (33.3) 2 (66.7)
Abbreviations: WD, well differentiated; MD, moderatelty differentiated; PD, poorly differentiated
＊ 
Significance
Relationship between clinicopathological features and expression of IL-33, ST2, and MCD
Table 1
Table 2
Number of patients MVD (mean ± SD) p
IL-33 High 41 43.46 ± 15.694 < 0.001
＊
Low 40 25.13 ± 11.346
＊
 Significance
Relationship between IL-33 expression and MVD
Table 2
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